Setanaxib by Calliditas Therapeutics for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Setanaxib overview
setanaxib (GKT-831; GKT-137831) is under development for the treatment of alport syndrome, kidney disease (nephropathy), primary biliary cholangitis (primary biliary cirrhosis), recurrent head and neck cancer squamous cell carcinoma, idiopathic pulmonary fibrosis. The drug candidate is administered orally. It selectively targets NOX4 and NOX1 over expressed in cancer associated fibroblast (CAF). It was also under development for the treatment of prostate cancer, liver fibrosis, kidney fibrosis, atherosclerosis, non alcoholic steatohepatitis, scleroderma, portal hypertension and kidney disease.
Calliditas Therapeutics overview
Calliditas Therapeutics formerly Pharmalink develops, identifies and commercializes pharmaceutical products for niche indications. The company’s pipeline products include Busulipo which is under Phase II clinical trials and Nefecon for IgA Nephritis which is under Phase II clinical trials. Its pipeline product also comprises Xepol XP-28 which is used for the treatment of post-polio syndrome and is under pre-license sales among others. Calliditas Therapeutics also partners with medical research institutions such as the Karolinska Institute and Uppsala University. It markets products under the brand TARPEYO. The company offers its products and services across Sweden. Calliditas Therapeutics is headquartered in Stockholm, Sweden.
For a complete picture of Setanaxib’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#Setanaxib #Calliditas #Therapeutics #Primary #Biliary #Cholangitis #Primary #Biliary #Cirrhosis #Likelihood #Approval
